Calliditas Therapeutics (CALT)

Calliditas Therapeutics Stock Price & Analysis


CALT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$12.55 - $27.50
Previous Close$14.2
Average Volume (3M)5.46K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$709.31M
Total Debt (Recent Filing)$878.00K
P/E Ratio-5.7
Next EarningsNov 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.50
Shares Outstanding26,624,784
Standard Deviation0.18
10 Day Avg. Volume9,966
30 Day Avg. Volume5,455
P/B Ratio14.78
P/S Ratio1.22
P/CF RatioN/A
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside-13.17% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Calliditas Therapeutics’s price range in the past 12 months?
Calliditas Therapeutics lowest stock price was $12.55 and its highest was $27.50 in the past 12 months.
    What is Calliditas Therapeutics’s market cap?
    Currently, no data Available
    When is Calliditas Therapeutics’s upcoming earnings report date?
    Calliditas Therapeutics’s upcoming earnings report date is Nov 17, 2022 which is in 49 days.
      How were Calliditas Therapeutics’s earnings last quarter?
      Calliditas Therapeutics released its earnings results on Aug 18, 2022. The company reported -$0.615 earnings per share for the quarter, beating the consensus estimate of -$0.827 by $0.212.
        Is Calliditas Therapeutics overvalued?
        According to Wall Street analysts Calliditas Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Calliditas Therapeutics pay dividends?
          Calliditas Therapeutics does not currently pay dividends.
          What is Calliditas Therapeutics’s EPS estimate?
          Calliditas Therapeutics’s EPS estimate is -$0.54.
            How many shares outstanding does Calliditas Therapeutics have?
            Calliditas Therapeutics has 29,578,793 shares outstanding.
              What happened to Calliditas Therapeutics’s price movement after its last earnings report?
              Calliditas Therapeutics reported an EPS of -$0.615 in its last earnings report, beating expectations of -$0.827. Following the earnings report the stock price went down -15.134%.
                Which hedge fund is a major shareholder of Calliditas Therapeutics?
                Currently, no hedge funds are holding shares in CALT


                Calliditas Therapeutics Stock Analysis

                Smart ScoreUnderperform
                The Calliditas Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Calliditas Therapeutics

                Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis